Journal of Clinical Oncology
Articles in this Issue
Colorectal organ preservation in Lynch syndrome: A tailored conservative surgical approach.
90 Background: For Lynch syndrome (LS)-associated colorectal cancers(CRC), existing guidelines prefer extended resection f...
Real-world treatment patterns and biomarker testing landscape of locally advanced gastric/gastroesophageal junction cancer (LA GC/GEJC) in China (SURPASS study).
304 Background: The treatment landscape for resectable locally advanced gastric/gastroesophageal junction cancer (LA GC/GE...
Initial biliary drainage strategy and in-hospital outcomes in malignant biliary obstruction: A national analysis.
583 Background: Optimal first-line biliary drainage for malignant biliary obstruction (MBO) remains debated. Endoscopic re...
Dose-dependent antitumor activity of HCB101 plus ramucirumab and paclitaxel in previously treated gastric cancer.
372 Background: Patients with advanced gastric adenocarcinoma who progress after first-line (1L) therapy have limited opti...
Multicenter retrospective study on treatment outcomes of gastric cancer with positive peritoneal cytology in Japan.
309 Background: Cytology-positive (CY1) gastric cancer is associated with poor prognosis, with a 5-year overall survival (...
A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).
730 Background: Nectin-4, a type I transmembrane protein, is critical for adherens junction formation and maintenance. Abe...
Intra-arterial gemcitabine versus intravenous gemcitabine: Pharmacokinetic and pharmacodynamic sub-study of the TIGeR-PaC phase 3 clinical trial.
732 Background: Localized, dual balloon catheter-mediated, intra-arterial delivery of gemcitabine (IAG) targeted to tumors...
Clinical outcomes of extended neoadjuvant FLOT for resectable gastroesophageal cancer.
356 Background: FLOT4 and ESOPEC established 4 preoperative/4 postoperative cycles of FLOT as the standard of care for non...
Once-daily oral paltusotine in the treatment of patients with carcinoid syndrome: Biomarker analysis results from a phase 2, randomized, parallel-group study.
632 Background: Paltusotine is an oral, nonpeptide, selective somatostatin receptor 2 agonist. In a phase 2 study, treatme...
Monthly alternating NALIRIFOX and GnP for metastatic pancreatic ductal adenocarcinoma (AltCAP).
TPS798 Background: Metastatic pancreatic ductal adenocarcinoma (mPDAC) remains a deadly disease with 5-year survival rates...
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: Final outcomes of a multicenter, phase II study (OGSG1902).
366 Background: Large type 3 (≥8 cm) and type 4 gastric cancers are associated with extremely poor prognoses. Neoadjuvant...
A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of RNK08954 in patients with advanced solid tumors with a KRAS G12D mutation.
729 Background: RNK08954 is a potent, oral and highly selective small molecule dual (On/OFF) non-covalent inhibitor of mut...
Neuroligin family genes expression associated with first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance).
179 Background: Neuroligins are a family of postsynaptic cell adhesion molecules that play a crucial role in synapse forma...
Acupuncture and acupressure to mitigate chemotherapy-induced peripheral neuropathy for GI cancer patients receiving oxaliplatin-based regimens: A pilot and feasibility study.
113 Background: Chemotherapy-induced peripheral neuropathy (CIPN) from oxaliplatin significantly affects quality of life a...
Postoperative minimal residual disease detection using tumor-informed circulating tumor DNA analysis in stage II–III gastric cancer: Updated analysis.
428 Background: Circulating tumor DNA (ctDNA) analysis enables detection of minimal residual disease (MRD), offering poten...
A phase 2/3 randomized study of BMS-986504 with nab-paclitaxel (nab-P) and gemcitabine (GEM) in first-line (1L) metastatic pancreatic ductal adenocarcinoma (PDAC) with homozygous <i>MTAP</i> deletion ( <i>MTAP</i> -del): MountainTAP-30.
TPS796 Background: MTAP -del is a genetic alteration found in 10–15% of all cancers and 20–25% of pati...
The Gastric Cancer Genome Explorer: A spatial and single cellular registry for identifying novel cellular markers and targets.
429 Background: The Gastric Cancer Registry (GCR) is a comprehensive resource that collects clinical information and sampl...
Lanreotide-octreotide switch in advanced gastrointestinal neuroendocrine tumors (giNETs).
623 Background: Somatostatin analogs (SSA) are the mainstay treatment for advanced giNETs. However, more needs to be under...
Continued zenocutuzumab treatment beyond progression in patients with <i>NRG1+</i> pancreatic cancer and cholangiocarcinoma: Analysis from the phase 2 eNRGy trial.
703 Background: While progressive disease (PD) is often considered a surrogate for treatment failure, continued therapy be...
Efficacy of neoadjuvant HER-2-targeted therapy in resectable HER-2-positive gastric and esophagogastric junction cancers: A meta-analytic perspective.
422 Background: Gastric, esophageal, and gastroesophageal junction cancers contribute significantly to global morbidity an...
Updated multicenter retrospective analysis of systemic treatments in well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
619 Background: Well-differentiated G3 GEP-NETs are rare and heterogeneous diseases, limiting phase III trials and definit...
Adjuvant mFOLFOXFIRI after curative-intent resection of oligometastatic colorectal cancer: Phase II FANTASTIC trial.
153 Background: The optimal postoperative systemic therapy in oligometastatic colorectal cancer (CRC) remains undefined. W...
Feasibility, safety and efficacy of endoscopic ultrasound-guided alpha radiotherapy for advanced pancreatic cancer: A pilot study.
721 Background: Pancreatic cancer (PDAC) is a devastating disease with limited locoregional treatment options. Diffusing A...
Hospital Frailty Risk Score and in-hospital mortality after pancreatectomy in adults ≥65: A national analysis (NIS 2020–2022).
738 Background: Frailty reflects physiological vulnerability and has emerged as a potent predictor of adverse surgical out...
Trends in mortality caused by gall bladder carcinoma in the United States population from 1999-2024: A CDC WONDER database analysis.
604 Background: Gallbladder cancer is a rare, highly fatal malignancy, often diagnosed at an advanced stage. Understanding...